SEARCH

SEARCH BY CITATION

REFERENCES

  • 1
    Smolen JS, Aletaha D. Patients with rheumatoid arthritis in clinical care. Ann Rheum Dis 2004; 63: 2215.
  • 2
    Pincus T, Stein CM, Wolfe F. “No evidence of disease” in rheumatoid arthritis using methotrexate in combination with other drugs: a contemporary goal for rheumatology care? Clin Exp Rheumatol 1997; 15: 5916.
  • 3
    Emery P, Salmon M. Early rheumatoid arthritis: time to aim for remission? Ann Rheum Dis 1995; 54: 9447.
  • 4
    Pinals RS, Masi AT, Larsen RA, and the Subcommittee for Criteria of Remission in Rheumatoid Arthritis of the American Rheumatism Association Diagnostic and Therapeutic Criteria Committee. Preliminary criteria for clinical remission in rheumatoid arthritis. Arthritis Rheum 1981; 24: 130815.
  • 5
    Wolfe F, Hawley DJ. Remission in rheumatoid arthritis. J Rheumatol 1985; 12: 24552.
  • 6
    Prevoo ML, van Gestel AM, van ‘t Hof MA, van Rijswijk MH, van de Putte LB, van Riel PL. Remission in a prospective study of patients with rheumatoid arthritis: American Rheumatism Association preliminary remission criteria in relation to the disease activity score. Br J Rheumatol 1996; 35: 11015.
  • 7
    Makinen H, Kautiainen H, Hannonen P, Sokka T. Frequency of remissions in early rheumatoid arthritis defined by 3 sets of criteria: a 5-year followup study. J Rheumatol 2005; 32: 796800.
  • 8
    Harrison BJ, Symmons DP, Brennan P, Barrett EM, Silman AJ. Natural remission in inflammatory polyarthritis: issues of definition and prediction. Br J Rheumatol 1996; 35: 1096100.
  • 9
    Eberhardt K, Fex E. Clinical course and remission rate in patients with early rheumatoid arthritis: relationship to outcome after 5 years. Br J Rheumatol 1998; 37: 13249.
  • 10
    Reilly PA, Cosh JA, Maddison PJ, Rasker JJ, Silman AJ. Mortality and survival in rheumatoid arthritis: a 25 year prospective study of 100 patients. Ann Rheum Dis 1990; 49: 3639.
  • 11
    Rasker JJ, Cosh JA. The natural history of rheumatoid arthritis over 20 years: clinical symptoms, radiological signs, treatment, mortality and prognostic significance of early features. Clin Rheumatol 1987; 6 Suppl 2: 511.
  • 12
    Rasker JJ, Cosh JA. The natural history of rheumatoid arthritis: a fifteen year follow-up study: the prognostic significance of features noted in the first year. Clin Rheumatol 1984; 3: 1120.
  • 13
    Fransen J, Creemers MC, van Riel PL. Remission in rheumatoid arthritis: agreement of the disease activity score (DAS28) with the ARA preliminary remission criteria. Rheumatology (Oxford) 2004; 43: 12525.
  • 14
    Balsa A, Carmona L, Gonzalez-Alvaro I, Belmonte MA, Tena X, Sanmarti R, and the EMECAR Study Group. Value of Disease Activity Score 28 (DAS28) and DAS28–3 compared to American College of Rheumatology-defined remission in rheumatoid arthritis. J Rheumatol 2004; 31: 406.
  • 15
    Wells GA, Boers M, Shea B, Brooks PM, Simon LS, Strand CV, et al. Minimal disease activity for rheumatoid arthritis: a preliminary definition. J Rheumatol 2005; 32: 201624.
  • 16
    Wolfe F, Anderson J, Burke TA, Arguelles LM, Pettitt D. Gastroprotective therapy and risk of gastrointestinal ulcers: risk reduction by COX-2 therapy. J Rheumatol 2002; 29: 46773.
  • 17
    Wolfe F, Flowers N, Burke TA, Arguelles LM, Pettitt D. Increase in lifetime adverse drug reactions, service utilization, and disease severity among patients who will start COX-2 specific inhibitors: quantitative assessment of channeling bias and confounding by indication in 6689 patients with rheumatoid arthritis and osteoarthritis. J Rheumatol 2002; 29: 101522.
  • 18
    Michaud K, Messer J, Choi HK, Wolfe F. Direct medical costs and their predictors in patients with rheumatoid arthritis: a three-year study of 7,527 patients. Arthritis Rheum 2003; 48: 275062.
  • 19
    Fries JF, Spitz PW, Kraines RG, Holman HR. Measurement of patient outcome in arthritis. Arthritis Rheum 1980; 23: 13745.
  • 20
    Wolfe F. A reappraisal of HAQ disability in rheumatoid arthritis. Arthritis Rheum 2000; 43: 275161.
  • 21
    Wolfe F, Michaud K, Pincus T. A composite disease activity scale for clinical practice, observational studies, and clinical trials: the Patient Activity Scale (PAS/PAS-II). J Rheumatol 2005; 32: 24105.
  • 22
    Wolfe F, Michaud K, Pincus T. Development and validation of the Health Assessment Questionnaire. II. A revised version of the Health Assessment Questionnaire. Arthritis Rheum 2004; 50: 3296305.
  • 23
    Doody MM, Hayes HM, Bilgrad R. Comparability of national death index plus and standard procedures for determining causes of death in epidemiologic studies. Ann Epidemiol 2001; 11: 4650.
  • 24
    Edlavitch SA, Baxter J. Comparability of mortality follow-up before and after the National Death Index. Am J Epidemiol 1988; 127: 116478.
  • 25
    Wolfe F, Michaud K, Pincus T, Furst D, Keystone E. The Disease Activity Score is not suitable as the sole criterion for initiation and evaluation of anti-tumor necrosis factor therapy in the clinic: discordance between assessment measures and limitations in questionnaire use for regulatory purposes. Arthritis Rheum 2005; 52: 38739.
  • 26
    Van der Heijde DM, van ’t Hof MA, van Riel PL, van Leeuwen MA, van Rijswijk MH, van de Putte LB. Validity of single variables and composite indices for measuring disease activity in rheumatoid arthritis. Ann Rheum Dis 1992; 51: 17781.
  • 27
    Van der Heijde DM, van 't Hof MA, van Riel PL, Theunisse LA, Lubberts EW, van Leeuwen MA, et al. Judging disease activity in clinical practice in rheumatoid arthritis: first step in the development of a disease activity score. Ann Rheum Dis 1990; 49: 91620.
  • 28
    Van der Heijde DM, van 't Hof M, van Riel PL, van de Putte LB. Development of a disease activity score based on judgment in clinical practice by rheumatologists. J Rheumatol 1993; 20: 57981.
  • 29
    Prevoo ML, van 't Hof MA, Kuper HH, van Leeuwen MA, van de Putte LB, van Riel PL. Modified disease activity scores that include twenty-eight–joint counts: development and validation in a prospective longitudinal study of patients with rheumatoid arthritis. Arthritis Rheum 1995; 38: 448.
  • 30
    Felson DT, Anderson JJ, Boers M, Bombardier C, Chernoff M, Fried B, et al. The American College of Rheumatology preliminary core set of disease activity measures for rheumatoid arthritis clinical trials. Arthritis Rheum 1993; 36: 72940.
  • 31
    Felson DT. Choosing a core set of disease activity measures for rheumatoid arthritis clinical trials. J Rheumatol 1993; 20: 5314.
  • 32
    Hoehler FK. Bias and prevalence effects on kappa viewed in terms of sensitivity and specificity. J Clin Epidemiol 2000; 53: 499503.
  • 33
    Feinstein AR, Cicchetti DV. High agreement but low kappa. I. The problems of two paradoxes. J Clin Epidemiol 1990; 43: 5439.
  • 34
    Stata Corporation. Stata statistical software: release 9.1. College Station (TX): Stata Corporation; 2005.
  • 35
    Aletaha D, Ward MM, Machold KP, Nell VP, Stamm T, Smolen JS. Remission and active disease in rheumatoid arthritis: defining criteria for disease activity states. Arthritis Rheum 2005; 52: 262536.
  • 36
    Wolfe F, Pincus T. The level of inflammation in rheumatoid arthritis is determined early and remains stable over the longterm course of the illness. J Rheumatol 2001; 28: 181724.
  • 37
    Breedveld FC, Kalden JR. Appropriate and effective management of rheumatoid arthritis [review]. Ann Rheum Dis 2004; 63: 62733.
  • 38
    Klareskog L, van der Heijde D, de Jager JP, Gough A, Kalden J, Malaise M, et al. Therapeutic effect of the combination of etanercept and methotrexate compared with each treatment alone in patients with rheumatoid arthritis: double-blind randomised controlled trial. Lancet 2004; 363: 67581.
  • 39
    Choy EH. Two is better than one? Combination therapy in rheumatoid arthritis. Rheumatology (Oxford) 2004; 43: 12057.
  • 40
    Quinn MA, Conaghan PG, O'Connor PJ, Karim Z, Greenstein A, Brown A, et al. Very early treatment with infliximab in addition to methotrexate in early, poor-prognosis rheumatoid arthritis reduces magnetic resonance imaging evidence of synovitis and damage, with sustained benefit after infliximab withdrawal: results from a twelve-month randomized, double-blind, placebo-controlled trial. Arthritis Rheum 2005; 52: 2735.
  • 41
    Sokka T, Kautiainen H, Hakkinen A, Hannonen P. Radiographic progression is getting milder in patients with early rheumatoid arthritis: results of 3 cohorts over 5 years. J Rheumatol 2004; 31: 107382.
  • 42
    Krishnan E, Fries JF. Reduction in long-term functional disability in rheumatoid arthritis from 1977 to 1998: a longitudinal study of 3035 patients. Am J Med 2003; 115: 3716.
  • 43
    Choi HK, Hernan MA, Seeger JD, Robins JM, Wolfe F. Methotrexate and mortality in patients with rheumatoid arthritis: a prospective study. Lancet 2002; 359: 11737.
  • 44
    Wolfe F, Hawley DJ, Cathey MA. Clinical and health status measures over time: prognosis and outcome assessment in rheumatoid arthritis. J Rheumatol 1991; 18: 12907.